Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: Early results in 148 patients

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 3, 2008, Pages 271-279

  Kennedy, Andrew S ^a   Dezarn, William A ^a   McNeillie, Patrick ^b   Coldwell, Doug ^c   Nutting, Charles ^d,e   Carter, Dennis ^d   Murthy, Ravi ^f   Rose, Steven ^g   Warner, Richard R P ^h   Liu, David ⁱ   Palmedo, Holger ^j   Overton, Carroll ^k   Jones, Bonita ^e   Salem, Riad ^l  

^a Wake Radiology Oncology   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d Sky Ridge Medical Center   (United States)

^e BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h MOUNT SINAI MEDICAL CENTER   (United States)

ⁱ Inland Imaging   (United States)

^j UNIVERSITY HOSPITAL BONN   (Germany)

^k Wake Radiology   (United States)

^l Northwestern Medical Center   (United States)

more..

Author keywords

Carcinoid; Liver; Microsphere; Neuroendocrine related liver metastases; Yttrium 90

Indexed keywords

MICROSPHERE; MICROSPHERE YTTRIUM 90; UNCLASSIFIED DRUG; YTTRIUM 90; RADIOPHARMACEUTICAL AGENT; YTTRIUM;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; BRACHYTHERAPY; CANCER SURVIVAL; DEATH; DISEASE COURSE; DISEASE SEVERITY; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; LABORATORY TEST; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PAIN; RADIATION DOSE FRACTIONATION; RADIOEMBOLIZATION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; CARCINOID; CLINICAL TRIAL; FOLLOW UP; GASTROINTESTINAL TUMOR; INSTRUMENTATION; LIVER TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PANCREAS TUMOR; PATHOLOGY; REMISSION; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CARCINOID TUMOR; EMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; YTTRIUM;

EID: 44949120870     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31815e4557     Document Type: Article

References (79)

1. Kaltsas G, Rockall A, Papadogias D, et al. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol. 2004;151:15-27.
2. Oberg K. Molecular imaging in diagnosis of neuroendocrine tumours. Lancet Oncol. 2006;7:790-792.
3. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79:813-829.
4. Oberg K. Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther. 2003;3:863-877.
5. Boudreaux JP, Putty B, Frey DJ, et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg. 2005;241:839-845; discussion 845-846.
6. Akerstrom G, Hellman P, Hessman O, et al. Management of midgut carcinoids. J Surg Oncol. 2005;89:161-169.
7. Oberg K. Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol. 2002;14:38-45.
8. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25: 458-511.
9. Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717-1751.
10. Oberg K. Neuroendocrine gastrointestinal tumors - a condensed overview of diagnosis and treatment. Ann Oncol. 1999;10(suppl 2):S3-S8.
11. Madoff DC, Gupta S, Ahrar K, et al. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol. 2006;17:1235- 1249; quiz 1250.
12. Abrams RA, King D, Wilson JF. Objective response of malignant carcinoid to radiation therapy. Int J Radiat Oncol Biol Phys. 1987;13: 869-873.
13. Chakravarthy A, Abrams RA. Radiation therapy in the management of patients with malignant carcinoid tumors. Cancer. 1995;75:1386-1390.
14. Gaitan-Gaitan A, Rider WD, Bush RS. Carcinoid tumor-cure by irradiation. Int J Radiat Oncol Biol Phys. 1975;1:9-13.
15. Keane TJ, Rider WD, Harwood AR, et al. Whole abdominal radiation in the management of metastatic gastrointestinal carcinoid tumor. Int J Radiat Oncol Biol Phys. 1981;7:1519-1521.
16. Samlowski WE, Eyre HJ, Sause WT. Evaluation of the response of unresectable carcinoid tumors to radiotherapy. Int J Radiat Oncol Biol Phys. 1986;12:301-305.
17. Schupak KD, Wallner KE. The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors. Int J Radiat Oncol Biol Phys. 1991;20:489-495.
18. Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998;83:2293-2301.
19. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104:1590-1602.
20. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med. 1994;120:302-309.
21. O'Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol. 2005;19:585-594.
22. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13:572- 581.
23. Ruszniewski P, Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion. 2000; 62(suppl 1):79-83.
24. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using Yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13-23.
25. Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65:412-425.
26. Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with (90)y microspheres: angiographic and technical considerations. Cardio-vasc Intervent Radiol. 2007;30:571-592.
27. Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics. 2005;25(suppl 1):S41-S55.
28. Salem R, Thurston KG. Radioembolization with 90-Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies, Part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251-1278.
29. Salem R, Thurston KG. Radioembolization with Yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies, Part 3: comprehensive literature review and future direction. J Vasc Interv Radiol. 2006;17:1571-1593.
30. Salem R, Thurston KG. Radioembolization with 90Yttrium micro-spheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies, Part 2: special topics. J Vasc Interv Radiol. 2006;17:1425-1439.
31. Ho S, Lau WY, Leung TW, et al. Clinical evaluation of the partition model for estimating radiation doses from Yttrium-90 microspheres in the treatment of hepatic Cancer. Eur J Nucl Med. 1997;24:293-298.
32. Ho S, Lau WY, Leung TW, et al. Partition model for estimating radiation doses from Yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23:947-952.
33. Kaltsas GA, Papadogias D, Makras P, et al. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer. 2005;12:683-699.
34. Modlin IM, Sandor A, Tang LH, et al. A 40-year analysis of 265 gastric carcinoids. Am J Gastroenterol. 1997;92:633-638.
35. Moertel C. Clinical management of advanced gastrointestinal Cancer. Semin Drug Treat. 1973;3:55-68.
36. Nolan T, Grady ED, Crumbley AJ. Regional internal radiation for hepatic Cancer. Minerva Oncol. 1973;1:104-106.
37. Norton JA. Endocrine tumours of the gastrointestinal tract. Surgical treatment of neuroendocrine metastases. Best Pract Res Clin Gastroenterol. 2005;19:577-583.
38. Oberg K. Carcinoid tumors: current concepts in diagnosis and treatment. Oncologist. 1998;3:339-345.
39. Simon N, Warner RRP, Baron MG, et al. Intra-arterial irradiation of carcinoid tumors of the liver. Am J Roentgenol Radium Ther Nucl Med. 1968;102:552-561.
40. Veenendaal LM, Borel Rinkes IH, Lips CJ, et al. Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol. 2006;4:35.
41. Zuetenhorst H, Taal BG, Boot H, et al. Long-term palliation in meta-static carcinoid tumours with various applications of meta-iodobenzyl- guanidin (MIBG): pharmacological MIBG, 131I-labelled MIBG and the combination. Eur J Gastroenterol Hepatol. 1999;11:1157-1164.
42. Soreide O, Berstad T, Bakka A, et al. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery. 1992; 111:48-54.
43. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000; 190:432-445.
44. Chen H, Hardacre JM, Uzar A, et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187:88-92; discussion 92-83.
45. Hibi T, Sano T, Sakamoto Y, et al. Surgery for hepatic neuroendocrine tumors: a single institutional experience in Japan. Jpn J Clin Oncol. 2007;37:102-107.
46. Musunuru S, Chen H, Rajpal S, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg 2006;141:1000-1004; discussion 1005.
47. Nave H, Mossinger E, Feist H, et al. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery. 2001;129:170-175.
48. Norton JA, Warren RS, Kelly MG, et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134:1057-1063; discussion 1063-1055.
49. Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169:36-42; discussion 42-33.
50. Reddy SK, Barbas AS, Marroquin CE, et al. Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis. J Am Coll Surg. 2007;204:372-382.
51. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroen-docrine tumors. Surg Oncol Clin N Am. 2003;12:231-242.
52. Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130:677- 682; discussion 682- 675.
53. Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol. 1999;10:397-403.
54. Clouse ME, Perry L, Stuart K, et al. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion. 1994;55(Suppl 3):92-97.
55. Dominguez S, Denys A, Menu Y, et al. Hepatic arterial chemoemboli-zation in the management of advanced digestive endocrine tumours. Ital J Gastroenterol Hepatol. 1999;31(Suppl 2):S213-215.
56. Drougas JG, Anthony LB, Blair TK, et al. Hepatic artery chemoembo-lization for management of patients with advanced metastatic carcinoid tumors. Am J Surg. 1998;175:408-412.
57. Kim YH, Ajani JA, Carrasco CH, et al. Selective hepatic arterial chemo-embolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest. 1999;17:474 - 478.
58. Kress O, Wagner HJ, Wied M, et al. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors-a retrospective single-center analysis. Digestion. 2003;68:94-101.
59. Loewe C, Schindl M, Cejna M, et al. Permanent transarterial emboliza-tion of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol. 2003;180:1379-1384.
60. Roche A, Girish BV, de Baere T, et al. Trans-catheter arterial chemo-embolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol. 2003;13:136-140.
61. Therasse E, Breittmayer F, Roche A, et al. Transcatheter chemoembo-lization of progressive carcinoid liver metastasis. Radiology. 1993;189: 541-547.
62. Kennedy AS, Van Echo DA, Murthy R, et al. Hepatic artery brachy-therapy for neuroendocrine carcinoma. Regul Pept. 2002;108:32.
63. McStay MK, Maudgil D, Williams M, et al. Large-volume liver metas-tases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology. 2005;237:718-726.
64. Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodo-benzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer. 2004;101:1987-1993.
65. Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoem-bolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer. 1993;71:2624-2630.
66. Clouse ME, Stokes KR, Kruskal JB, et al. Chemoembolization for hepatocellular carcinoma: epinephrine followed by a doxorubicin-ethio-dized oil emulsion and gelatin sponge powder. J Vasc Interv Radiol. 1993;4:717-725.
67. Simon N, Warner RRP, Baron MG, et al. Intra-arterial irradiation of carcinoid tumors of the liver. Am J Roentgenol Radium Ther Nucl Med. 1968;102:552-561.
68. Ho AS, Picus J, Darcy MD, et al. Long-term outcome after chemoem-bolization and embolization of hepatic metastatic lesions from neuroen-docrine tumors. AJR Am J Roentgenol. 2007;188:1201-1207.
69. Gray BN, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel Cancer. Ann Oncol. 2001;12: 1711-1720.
70. Kennedy AS, Dezarn WA, McNeillie P, et al. Fractionation, dose selection, and response of hepatic metastases of neuroendocrine tumors after 90Y microsphere brachytherapy. Brachytherapy. 2006;5:103-104.
71. Kennedy AS, Nutting C, Coldwell D, et al. Pathologic response and microdosimetry of 90Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60:1552-1563.
72. Sharma RA, Van Hazel GA, Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25:1099-1106.
73. Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metasta-ses. J Gastrointest Surg. 2001;5:294-302.
74. Stubbs RS, O'Brien I, Correia MM. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg. 2006;76:696-703.
75. Ho S, Lau WY, Leung TW, et al. Internal radiation therapy for patients with primary or metastatic hepatic cancer: a review. Cancer. 1998;83: 1894-1907.
76. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40:583- 592.
77. Lau WY, Leung WT, Ho S, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer. 1994;70:994-999.
78. Kennedy AS, Salem R. Comparison of two 90Yttrium microsphere agents for hepatic artery brachytherapy. In: Proceedings of the 14th International Congress on Anti-Cancer Treatment. 2003;1:156.
79. Steel J, Baum A, Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of cisplatin versus 90-yttrium microspheres (therasphere). Psychooncology. 2004; 13:73-79.